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Summary: The major structural components of high density lipoproteins were determined in the sera of 638
male employees aged 40 years and older. It was demonstrated that the HDL apolipoprotein A-I/HDL
cholesteröl ratio äs well äs the HDL apolipoprotein A-II/HDL eholesterol ratio are similarly correlated to
a cumulative score of established risk factors for atherosclerosis. Most important, however, is the finding
that the correlation of these ratios to the risk factor rating of atherosclerosis is found in subgroups with normal
or elevated HDL cholesteröl values. Furthermore, it is shown that the relative content of apolipoproteins -
and A-II in individual HDL is partly dependent on the plasma concentration of HDL cholesteröl and
triglycerides.
It is concluded that HDL composition may have an additional predictive significance for the development
of atherosclerosis.
HDL^Apolipoprotein A^L· und HDL-Apolipoprotein A-II-Konzentrationen bei männlichen Betriebsangehörigen
in Westfalen im Alter von 40 Jahren und darüber
Zusammenfassung: Im Serum von 638 männlichen Betriebsangehörigen im Alter von 40 Jahren und darüber
wurden die Hauptstrukturkomponenten der "high density" Lipoproteine untersucht. Es wird gezeigt, daß
sowohl das HOL-Applipoprotein A-I/HDL-Cholesterin-Verhältnis als auch das HDL-Apolipoprotein A-II/
HDL-Cholesterin-Verhältnis vergleichbar mit einem kumulativen Score von bekannten Risikofaktoren der
Atherosklerose korreliert ist. Am bedeutsamsten ist die Beobachtung, daß die Korrelation zwischen diesen
Quotienten und dem Risiko^Score in Untergruppen mit normalen und erhöhten HDL-Cholesterinwerten
erhalten bleibt. Dariiberhiüaus wird gezeigt, daß der relative Anteil von Apolipoprotein A-I und Apolipopro-
tein A-II in den HDL teilweise von der Konzentration von HDL-Cholesterin und Triglyceriden im Plasma
abhängt.
Die Ergebnisse deuten darauf hin, daß der HDL-Komposition eine zusätzliche prädiktive Bedeutung für die
Entwicklung der Atherosklerose zukommt.
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Introduction
In recent epidemiological (1—4) and clinical studies
(5 — 6) the analysis of high density lipoprotein cho-
lesterol (HDL cholesterol) has been shown to be a
risk indicator for coronary heart disease. In contrast
to HDL cholesterol, the possible relationship of HDL
apolipoproteins to the risk of coronary heart disease
has not yet been thoroughly investigated. Several
clinical studies have demonstrated low levels of apoli-
poprotein A-I in subjects with coronary heart disease
(7 — 9), while apolipoprotein A-II in patients with
coronary heart disease has been found to be low (10,
11) or unchanged (6, 8). In contrast to these clinical
studies there is a lack of the prospective epidemiologi-
cal data needed to demonstrate the predictive potency
of HDL apolipoproteins with respect to coronary
heart disease. Recently, from initial results of our
epidemiological study in Company employees in
Westphalia, it was demonstrated that HDL apolipo-
protein A-I correlates with several risk factors for
coronary heart disease but fails to correlate with the
risk factors triacylglycerol and relative body weight
(12). To date, no comparable studies on HDL apoli-
poprotein A-II are available. For a greater insight
into the relationship between HDL apolipoproteins
and the risk factors for coronary heart disease, we
measured both HDL apolipoproteins A-I and A-II
in 638 male Company employees in addition to HDL
cholesterol. Since the incidence of coronary heart
disease in women and in men under 40 years of age
is very low, our study was limited to individuals aged
40 years and above.
Materials and Methods
Sample material
Sera were obtained from male employees aged 40 years and
over. All of these were participants in the "Prospective epidemi-
ological study of Company employees in Westphalia" (13). Data
given here are cross sectional. The proband's mean age was
49 ± 6 years, the maximum age being 64 years; observed body
weight expressed s Broca index ranged from 69% to 151%
with a mean value of 106.6% ± 12.2%.
Analysis of HDL components
HDL components were analysed in the supernatant after preci-
pitation of apolipoprotein B-containing lipoproteins with phos-
photungstic acid/MgC!2 using the Boehringer Mannheim Test
Combination (test no. 1442434) (14). HDL cholesterol was
analysed enzymatically using the CHOD-PAP method
(Boehringer Mannheim, test combination nol 237574) (14).
HDL phosphatidyl choline was determined with an enzyinatic
colour test using the centrifugal analyser Cobas Bio (Hoffmann
La R che) s described preViously (15).
Apolipoprotein A-I was determined turbidimetrically using the
Cobas Bio analyser.
The incubation mixture contained:
— 300 μΐ phosphate-buffered polyethyleneglycol solution (Im-
munochemical System Beckman)
- 20 μΐ d uted sample (dilution l: 160 with 9 g/l NaCl)
— 20 μΐ antibody solution (Behring antibody no. 103315 B
was diluted with l : 2.5 with 9 g/l NaCl)
- 10μ1Η2Ο
As a blank, 300 μΐ phosphate-buffered polyethyleneglycol solu-
tion was used, containing 20 μΐ diluted sample (dilution l: 160
with 9 g/l NaCl) and 10 ul H2O. After an incubation period at
25 °C changes in turbidity were recorded 30 times. For calibra-
tion, a Standard solution of known concentration (Behring
Apolipoprotein A Standard Serum Lot No. A 041206 K) was
d uted l: 30, l: 60, l: 120, l: 240, and l : 480 with 9 g/l NaCL
The parameter list for the Cobas Bio reads s follows:
1 unit
2 calculation factor
3 Standard l conc
3 Standard 2 conc
3 Standard 3 conc
3 Standard 4 conc
3 Standard 5 conc
6 limit
7 temperature ( °C)
8 type of analysis
9 wavelength (nm)
10 sample dilution (μΐ)
11 diluent volume (μΐ)
12 reagent volurne (μΐ)
13 incubation tinie (s)
14 start reagent volume (μΐ)
15 time of first reading (s)
16 time interval (s)
























Using this turbidimetric method identical results were obtained
when compared with data observed using kinetic nephelometry
(16).
HDL apolipoprotein A-II was measured by turbidimetry using
the Cobas Bio analyser s described in detail elsewhere (17).
LDL cholesterol
LDL cholesterol was calculated using the Friedewald method
(18).
Total cholesterol, triacylglycerol, uric acid
Serum levels of cholesterol, triacylglycerol, glucose and uric
acid were determined with the SMAC II Analyser (Techiucon
GmbH, Bad V bel, FRG) s described elsewhere (13).
Statistics
For statistical calculations we used the statistical package for
the social sciences (SPSS). To describe felationships to risk
factors Spearman's correlation coefflcients were chosen since
the risk factors were not always normally distributed, s proved
by the Kolmogorov-Smirnow test. The correlations pf apolipo-
proteins to the coronary risk score were calculated by KendalTs
τ because of the high number of tied ranks. Differences in the
distribution between subgroups were tested by the Kruskal-
' Wallis test. The level of significance was set at 0.05.
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Results
Distribution of HDL apolipoprotein A-I and
A-II
Figure l shows the HDL apolipoprotein A-I values
measured in Company employees 40 years and older.
The parameters of distribution were:
mean: 1.444 g/l,





The corresponding values of apolipoprotein A-II are
shown in figure 2:
mean: 0.427 g/l,





Correlation to cumulative risk factor rating
To test the relationship between HDL cholesterol,
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Fig. 1. HDL apolipoprotein A-I values (g/l) in 616 normal male individuals 40 years and older. Epidemiological study of Company
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Fig. 2. HDL apolipoprotein A-II values (g/l) in 638 normal male individuals 40 years and older. Epidemiological study of
Company employees in Westphalia - cross sectional data. On the horizontal axis the upper bounds are given.
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HDL apolipoprotein A-II/HDL cholesterol ratio and
risk factors, a cumulative risk factor rating was estab-
lished for each subject. It was based on relative
weight, diastolic blood pressure, cigarette smoking,
cholesterol value and exercise. A score of 0, l or 2
was allocated for each of these measurements (tab.
1) and the sum of these individual scores was taken
s the cumulative rating (19). The relation between
each of the three parameters and increasing risk score
was significant (p < 0.001 each). The distribution
of the three parameters in the subgroups with a
cumulative risk rating score of 0, l, 2—6 are demon-
strated in figures 3, 4 and 5 where additionally the
median values are indicated. The differences in the
distributions between the subgroups are significant
(Kruskal-Wallis test, p < 0.001 each). The relation-
ship between the HDL apolipoprotein A-I/HDL cho-
lesterol ratio and the cumulative risk rating score was
comparable to the relationship of HDL cholesterol
and the risk\score (tab. 2).
Tab. 1. Risk rating score sheet.
0 point l point 2 points
Relative body weight <100 100-120 >120
(Broca Index, %)







non-smoker 1 — 2 0 > 20
< 6.72 6.72-7.75 > 7.75
very slightly inactive
active active
An analysis of subgroups with low (< 0.91 mmol/1),
normal (0.91 — 1.40 mmol/1) or elevated (> 1.40
mmol/1) HDL cholesterol values irevealed that the
two ratios were related to the cumulative risk factor
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Fig. 3. HDL cholesterol in relation to eumulative risk factor rating. A '9' is printed if 9 or more men»have equal values.
r (Kendall) = -0.280 (p < 0.001)
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Tab. 2. Correlation coefficients (Kendatfs τ) between the cor-
onary risk score and HDL-cholesterol, HDL apolipo-







; < 0.907 mmol/1 n = 112
HDL cholesterol 0.260***
; 0.907 -1.424 mmol/1 n = 369
HDL cholesterol 0.149*
> 1.424mmol/ n = 135
Total group 0.300***
n = 616
* p < 0.05
** p < 0.01
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n = 114 n = 114
0.206*** -0.109*
n = 381 n = 381
0.206 -0.097
n = 142 n = 142
0.287*** -0.280***























lesterol values (tab. 2). Therefore, it seems possible
that in subjects with normal or elevated HDL cho-
lesterol values, high ratios of HDL apolipoprotein
A-I/HDL cholesterol and HDL apolipoprotein A-II/
HDL cholesterol reflects an increased risk of develop-
ing coronary heart disease.
HDL apolipoprotein A-I/HDL apolipopro-
tein A-II ratio
The HDL apolipoprotein A-I/HDL apolipoprotein
A-II ratio was positively correlated with HDL cho-
lesterol (r = 0.194, p < 0.001) (tab. 3, fig. 6). Fur-
thermore, in individuals with low HDL cholesterol
values (< 0.907 mmol/1), a relatively low HDL-apoli-
poprotein A-I/HDL apolipoprotein A-II ratio (3.23
± 0.47) was calculated. Individuais with high HDL
cholesterol values (> 1.41 mmol/1) showed signifi-
cantly higher HDL apolipoprotein A-I/HDL apolipo-
protein A-II ratios (3.67 ± 0.52, p < 0.001). The
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Risk rating
6.00 7.00 8.00 9.00
: Fig. 4. HDL apolipoprotein A-I/HDL cholesterol ratio in relation to cum lative risk factor rating. A 49' is printed if 9 or raore
| men have equal values.
!
 r (Kendall) = -0.287 (p < 0.001)
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Tab. 3. Correlation coefTicients (Spearman rank correlation)
between the ratio, HDL apolipoprotein A-I/HDL apo-
lipoprotein A-II, and cholesterol, triacylglycerol, HDL









* p < 0.01
ratio was negatively correlated with triacylglycerol (r:
-0.124, p < 0.001) (flg. 7, tab. 3). In individuals
with triacylglycerol < 1.71 mmol/1, the HDL apoli-
poprotein A-I/HDL apolipoprotein A-II ratio was
found to be higher (3.51 ± 0.48) than in individuals
with triacylglycerol ranging from 1.71 to 2.27 mmol/1
(3.33 ± 0.43) or hypertriacylglycerolaemic indivi-
duals > 2.27 mmol/1 (3.33 ± 0.49). On the other
band, there were no differences in the HDL apolipo-
protein A-I/HDL apolipoprotein A-II ratio between
hypertriacylglycerolaemic individuals and individuals
with medium triacylglycerol values.
Discussion
In our present study we report only data on men 40
years and older, since this group obviously has a
higher coronary risk than women or men under 40.
With respect to HDL cholesteibl and HDL apolipo-
protein A-I, the data obtained from men 40 years and
older did not differ significantly from data reported
previously for Company employees from 25 to 64
years old (12). In addition to our previous study,
HDL apolipoprotein A-II values were also measüred.
As previously reported (19) and äs again shown by
the present results, HDL cholesterol has a negative
correlation to the individual cumülative coronary risk
based on the most frequent risk factors, obesity, hy-
pertension, cigarette srnoking, cholesterol and exer-
cise. In comparison with HDL cholesterol, the rela-
tion of both ratios, HDL apolipoprotein A-I/HDL
cholesterol and HDL apolipoprotein A-II/HDL chö-
lesterol, to the individual cumülative risk did not
differ. Furthermore, in individuals with normal or
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° Risk rating
Fig. 5. HDL apolipoprotein A-II/HDL cholesterol ratio in relation to cumülative risk factor rating. A '9' is printed if 9 or more
men have equal values. ·
r (Kendall) = 0.300 (p < 0.001)
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risk was associated with a higher ratio of HDL apoli-
poprotein A-I/HDL cholesterol and HDL apolipo-
protein A-II/HDL cholesterol. The reason for this
observation may lie in possible changes in mass and
composition of HDL subfractions caused by risk
factors and in different associations of HDL subfrac-
tions to coronary risk. It is known that changes in
plasma HDL level mainly affect HDL2 (20) and that
an inverse correlation exists between HDL and
VLDL in plasma (21). Furthermore, it has been
shown that a less dense HDL2 subfraction (relative
high lipid/apolipoprotein ratio) is epidemiologically
associated with reduced coronary heart disease, while
a more dense HDL3 subfraction (relatively low lipid/
apolipoprotein ratio) is thought to be unrelated to
such disease (22, 23). Nevertheless, recent studies
have shown that HDL in individuals with hypertri-
acylglycerolaemia mainly consist of HDL3, which are
enriched with apolipoproteins and triglycerides and
which are depleted of cholesterol (24). Furthermore,
it has been reported that alcohol consumption, which
is known to be associated with high HDL cholesterol
(25 — 27) and frequently with hypertriacylglycerol-
aemia (28, 29), mainly resulted in an enhanced level
of HDL3 mass without affecting HDL2 mass (30).
It has been shown that the apolipoprotein A-I/apoli-
poprotein A-II ratio in HDL/2 is higher than that in
HDL3 (31, 32). Therefore, in individuals with heigh
HDL cholesterol levels (which are associated with
lower triacylglycerol) and a similarly high apolipo-
protein A-I/apolipoprotein A-II ratio, a higher
HDL2/HDL3 ratio may exist in comparison to indivi-
duals with lower HDL cholesterol levels (which are
associated with higher triacylglycerol) and a similarly
low apolipoprotein A-I/apolipoprotein A-II ratio.
However, it is of interest to note that the HDL
lipoprotein composition in our study did not differ
between individuals with moderate hyperlipoprotein-
aemia and individuals with obviously enhanced lipid
levels. Possibly, in hypertriacylglycerolaemics, the
HDL apolipoprotein A-I/apolipoprotein A-II ratio
may additionally be a reflection of the change in
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Fig. 6. Bivariate distribution of HDL apolipoprotei A-I/HDL apolipoprotein A-II ratio and HDL cholesterol.
r (Spearmari) = 0.194 (p < 0.01)
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Fig. 7. Bivariate distribution of HDL apoüpoprotein A-I/HDL apolipoprotein A-II ratio and triacylglycerol.
r (Spearman) = —0.124 (p < 0.01)
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